F90
Conditions
Interventions
Group 1: Adult patients with attention deficit hyperactivity disorder (ADHD):
Computerized tests of visuospatial working memory precision, capacity, and perception are conducted, along with questionna
Sponsors
Klinik für Psychiatrie, Psychosomatik und Psychotherapie
Eligibility
Sex/Gender
All
Age
18 Years to 40 Years
Inclusion criteria
Inclusion criteria: -Normal or corrected vision -Signed declaration of consent -For patients: Completed diagnosis of ADHD (according to DSM-5) (checked according to the German version of the DIVA 2.0 interview) -For patients: Global Impressions Scale (CGI) = 4 & ADHD Rating Scale for Adults (ADHD-RS-V) = 30
Exclusion criteria
Exclusion criteria: -Persons with a current or past neurological disease -Persons with a serious somatic illness (incl. cancer, chemotherapy, etc.) -Drug use (incl. marijuana) in the last 28 days -Premorbid IQ < 70 -Color blindness (verified by Ishihara test) -For control subjects: current or past psychiatric illness or first-degree relatives with a current or past psychiatric illness -In patients: Contraindication to methylphenidate (MPH) -In patients: Use of methylphenidate or other stimulants in the past 6 months -In patients: current comorbid severe psychiatric illness (including active alcohol and drug abuse)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The goal of the study is to study the utility of spatial working memory precision as a biomarker for methylphenidate (MPH) treatment in adult ADHD. This is a naturalistic biomarker study without a primary endpoint. Once patients receive a MPH dose they are satisfied with and decide together with their treating psychiatrist that MPH dose is not increased any further, they have completed the study. | — |
Secondary
| Measure | Time frame |
|---|---|
| The visuospatial working memory precision is the secondary endpoint of the study. It is assessed using a computerized task in which participants memorize the position of colored dots presented sequentially in a circular array and reproduce the target location after a short delay. The degree of deviation from the original position serves as a measure of precision. In ADHD patients, working memory precision is measured before the initiation of methylphenidate (MPH) treatment and after each weekly dose increase, across a total of six sessions. In healthy control subjects, six weekly assessments are also conducted without medication. The aim is to evaluate working memory precision as a biomarker to predict the optimal individual MPH dose in adult ADHD. | — |
Countries
Germany
Contacts
Public ContactRobert Bittner
Klinik für Psychiatrie, Psychosomatik und Psychotherapie
Outcome results
None listed